Moreover, results with combined pinometostat and FLT3 inhibitor were recently reported for pediatric AML patients, confirming that targeting DOT1L with pinometostat sensitizes AML cells to further treatment with the multi-kinase inhibitor sorafenib [56]. Here, DOT1L is linked to acute myeloid leukemia.